why to use digoxin in heart failure
play

Why to use digoxin in heart failure? Yves Juillire, Cardiology, - PowerPoint PPT Presentation

Why to use digoxin in heart failure? Yves Juillire, Cardiology, ILCV, CHU Nancy-Brabois, France Digitalis purpurea Representation of the extracellular loops Binding orientation of digoxin and the transmembrane domain regions of the sheep


  1. Why to use digoxin in heart failure? Yves Juillière, Cardiology, ILCV, CHU Nancy-Brabois, France Digitalis purpurea Representation of the extracellular loops Binding orientation of digoxin and the transmembrane domain regions of the sheep α 1-subunit of Na + ,K + -ATPase From HEENAN SM et al, J Mol Graph Model 2005; 23: 465-75

  2. Presenter Disclosure Information ✸ I declare having professional relationships with the following industrial companies: - AstraZeneca for financial support of the entire I-CARE program - Bayer, Servier and Novartis for participating to boards - Abbott Vascular, Bristol-Myers-Squibb, Novartis, Sanofi-Aventis, Schering-Plough for participation to investigational trials as French national coordinator and/or to meetings as speaker Digitalis purpurea

  3. 1950s - 1980s 1980s - 2000 Hemodynamic Model Neurohormonal Model Reduced contractility Progressive remodeling with impaired Pump dysfunction myocardial performance Treatment: Treatment: Positive inotropic drugs to stimulate Prevention of progression with contractility neurohormone blockers Vasodilators to « unload » the heart Conventional drugs Diuretics Conventional drugs Digitalis Diuretics Digitalis Emerging therapies Endothelin blockers Neutralendopeptidase inhibitors Heart Failure: a changing paradigm Chimeric atrial peptides Francis GS, Am J Med 2001; 110(7A): 37S-46S Cytokine inhibitors Matrix metalloproteinase inhibitors

  4. Long-term digitalis therapy improves LV function in HF ARNOLD SB et al, N Engl J Med 1980; 303: 1443-1448 Acute readministration Discontinuation

  5. Effect of digoxin withdrawal in pts with mild to moderate chronic CHF: the PROVED trial URETSKY BF et al. J Am Coll Cardiol 1993; 22: 955-962 Withdrawal of digoxin from pts with chronic HF treated with ACE inhibitors: the RADIANCE trial PACKER M et al, N Engl J Med 1993; 329: 1-7

  6. DIG Study Digitalis Investigation Group, N Engl J Med 1997; 336: 525-533

  7. Clinical benefits of low serum digoxin concentrations in heart failure ADAMS KF et al, JACC 2002; 39: 946-953 From PROVED and RADIANCE studies

  8. Association of serum digoxin concentration and outcomes in patients with heart failure (DIG trial) RATHORE SS et al, JAMA 2003; 289: 871-878

  9. Association of serum digoxin concentration and outcomes in patients with heart failure (DIG trial) RATHORE SS et al, JAMA 2003; 289: 871-878

  10. Digoxin and reduction in mortality and hospitalization in HF: a comprehensive post-hoc analysis of the DIG trial AHMED A et al, Eur Heart J 2006; 27: 178-186

  11. Relationship of serum digoxin concentration to mortality and morbidity in women in the DIG trial ADAMS KF et al, J Am Coll Cardiol 2005; 46: 497-504 HR for all-cause mortality or HR for all-cause mortality first hospitalization due to WHF

  12. Heart rate as a risk factor in CHF (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial BÖHM M et al. Lancet 2010; 376: 886-894

  13. Percentage of Digoxin in HF studies 92% 53% ELITE II MADIT 58% CONSENSUS CIBIS II 50% 33% 67% V-HeFT- I 100% CIBIS III Val-HeFT MADIT-II 57% ??% V-HeFT- II 100% AVID 46% MERIT-HF 63% VALIANT SOLVD T 66% CHARM-A SCD-HeFT 63% US Carv Trial 91% 45% SOLVD P 12% COMPANION ??% COPERNICUS 67% CHARM-I 58% SAVE 25% CARE-HF 43% CAPRICORN ??% CHARM-P 28% AIRE 12% SHIFT 22% SENIORS 39% I-Preserve 13% 26% TRACE A-HeFT 59% BEST 93% RALES 75% ATLAS ??% GESICA 77% 61% COMET EPHESUS ??% OVERTURE 59% CORONA 34% RECOVER 55% EMPHASIS 27% PEP-CHF 11% ANDROMEDA 31% RENAISSANCE 83% V-HeFT III 75% HF-Action 43% PRAISE 99% Between 11% and 100%, mean: 55%

  14. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction CASTAGNO D et al. Eur Heart J 2012; 33: 1137-1141

  15. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction CASTAGNO D et al. Eur Heart J 2012; 33: 1137-1141

  16. Mortality and morbidity of HF treated with digoxin. A propensity-matched study ANDREY JL et al. Int J Clin Pract 2011; 65: 1250-1258 All-cause survival Mean F/U: 46.1±11.2 mths

  17. Mortality and morbidity of HF treated with digoxin. A propensity-matched study ANDREY JL et al. Int J Clin Pract 2011; 65: 1250-1258 Cardiovascular mortality

  18. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure FREEMAN JV et al. Circ Cardiovasc Qual Outcomes 2013; in press. Mean daily dose of digoxin: 0.15±0.05 mg 0.14±0.04 mg among those who died 0.15±0.05 mg among those who did not die Serum digoxin concentration: never measured in 30% only once in 27% more than once in 43% Mean serum digoxin concentration: At the first one-month measurement: 0.93±0.21 ng/ml in men 1.12±0.32 ng/ml in women During F/U: 1.02±0.48 ng/ml 1.01±0.46 ng/ml in those who died 1.04±0.55 ng/ml in those who did not die

  19. What is the economic value of digoxin therapy in CHF patients? (DIG trial) EISENSTEIN EL et al, J Card Fail 2006; 12: 336-342

  20. ✸ Number of pts needed to treat for 1 year to avoid 1 CV death or 1 hospitalization for HF:……. 25 ✸ Cost for Ivabradine: - Total French price: 63.35 € /mo 19000 € for 25 pts/yr ✸ Cost for Digoxin: - Total French price: 2.75 € /mo 825 € for 25 pts/yr

  21. CONCLUSION ✸ One of the first cardiovascular agents used in medicine ✸ Large morbidity benefit: - at least as large as that seen for either ACE-inhibitors or ivabradine in heart failure ✸ Problematic underprescription of digoxin because of: - minimizing the very substantial benefit in morbidity - overlooking the role of background therapy in the most of large trials testing ACE-inhibitors or beta-blockers - Lack of an extensive marketing for a low cost generic drug ✸ Importance of a low serum digoxin concentration < 0.9 ng/ml

  22. « After all, in spite of opinion, prejudice or error, time will fix the real value upon this discovery » Sir William WHITERING Birmingham, July 1, 1785 In: « An account of the foxglove and some of its medical uses with practical remarks on dropsy and other diseases »

Recommend


More recommend